Ironwood Pharmaceuticals (IRWD) Retained Earnings (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Retained Earnings across 17 years of filings, most recently posting -$795000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$795000.0, up 99.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$795000.0 (up 99.95% YoY), and the FY2025 annual result was -$1.7 billion, down 181434.56% from the prior year.
• Retained Earnings came in at -$795000.0 for Q1 2026 at Ironwood Pharmaceuticals, up from -$1.7 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $923000.0 in Q4 2024 to a low of -$1.7 billion in Q1 2025.
• The 5-year median for Retained Earnings is -$745.2 million (2022), against an average of -$820.9 million.
• Peak annual rise in Retained Earnings reached 130.45% in 2024, while the deepest fall reached 225962.63% in 2024.
• Ironwood Pharmaceuticals' Retained Earnings stood at -$696.4 million in 2022, then jumped by 99.56% to -$3.0 million in 2023, then jumped by 130.45% to $923000.0 in 2024, then tumbled by 181434.56% to -$1.7 billion in 2025, then surged by 99.95% to -$795000.0 in 2026.
• The last three Retained Earnings figures came in at -$795000.0 (Q1 2026), -$1.7 billion (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.